Diisopropylethylamine → 2-(2-Isopropyl-5-methyl-2H-[1,2,4]triazol-3-yl)-8-(1-isopropylpiperidin-4-ylsulfanyl)-4,5-dihydro-6-oxa-1,3a-diazabenzo[e]azulene

HRID 1530432Notes

Reaction equation

HRID 1530432 reaction equation
Br[C:2]1[CH:24]=[CH:23][C:5]2[C:6]3[N:10]([CH2:11][CH2:12][O:13][C:4]=2[CH:3]=1)[CH:9]=[C:8]([C:14]1[N:15]([CH:20]([CH3:22])[CH3:21])[N:16]=[C:17]([CH3:19])[N:18]=1)[N:7]=3.[CH:25]([N:28]1[CH2:33][CH2:32][CH:31]([SH:34])[CH2:30][CH2:29]1)([CH3:27])[CH3:26].CC1(C)C2C(=C(P(C3C=CC=CC=3)C3C=CC=CC=3)C=CC=2)OC2C(P(C3C=CC=CC=3)C3C=CC=CC=3)=CC=CC1=2.CCN(C(C)C)C(C)C>O1CCOCC1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.[Pd].[Pd]>[CH:20]([N:15]1[C:14]([C:8]2[N:7]=[C:6]3[N:10]([CH2:11][CH2:12][O:13][C:4]4[CH:3]=[C:2]([S:34][CH:31]5[CH2:32][CH2:33][N:28]([CH:25]([CH3:27])[CH3:26])[CH2:29][CH2:30]5)[CH:24]=[CH:23][C:5]=43)[CH:9]=2)=[N:18][C:17]([CH3:19])=[N:16]1)([CH3:22])[CH3:21]

Participants

7

Reactant 4

HCID 81531DiisopropylethylamineHCID 6360441,1'-(9,9-Dimethyl-9H-xanthene-4,5-diyl)bis(1,1-diphenylphosphine)HCID 199366054-Piperidinethiol, 1-(1-methylethyl)-HCID 582043229-Bromo-2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine

Product 1

HCID 683126152-(2-Isopropyl-5-methyl-2H-[1,2,4]triazol-3-yl)-8-(1-isopropylpiperidin-4-ylsulfanyl)-4,5-dihydro-6-oxa-1,3a-diazabenzo[e]azuleneYield 70.5%

Reagents, catalysts & solvents 2

HCID 9811564Bis(dibenzylideneacetone)palladiumCatalystHCID 312751,4-DioxaneSolvent

Conditions

Temperature
120 °C

Procedure

A mixture of 8-bromo-2-(2-isopropyl-5-methyl-2H-[1,2,4]triazol-3-yl)-4,5-dihydro-6-oxa-1,3a-diazabenzo[e]azulene (150 mg, 0.386 mmol), 1-isopropylpiperidine-4-thiol (92 mg, 0.579 mmol), Pd2(dba)3 (18 mg, 5 mol %), XantPhos (23 mg, 10 mol %) and DIPEA (0.27 mL, 1.54 mmol) in dioxane (4 mL) was purged with nitrogen and then heated at 120° C. for 1 h using microwave irradiation. After cooling to RT, the crude mixture was diluted with DCM (75 mL) and purified by column chromatography (Si-PCC, gradient 0-6% 2N NH3/MeOH in DCM followed by C18, gradient 20-50% MeOH in 0.5% TFA/H2O). The product containing fractions were combined and concentrated in vacuo. The resulting residue was loaded onto an Isolute® SCX-2 cartridge which was washed with MeOH and the product eluted with 0.5M NH3/MeOH. The basic fractions were concentrated under reduced pressure affording 2-(2-Isopropyl-5-methyl-2H-[1,2,4]triazol-3-yl)-8-(1-isopropylpiperidin-4-ylsulfanyl)-4,5-dihydro-6-oxa-1,3a-diazabenzo[e]azulene as a colorless solid (127 mg, 70%). LCMS: RT 3.00 min [M+H]+ 467.1

Workup

  1. customwas purged with nitrogen
  2. custommicrowave irradiation
  3. temperatureAfter cooling to RT
  4. additionthe crude mixture was diluted with DCM (75 mL)
  5. custompurified by column chromatography (Si-PCC, gradient 0-6% 2N NH3/MeOH in DCM followed by C18, gradient 20-50% MeOH in 0.5% TFA/H2O)
  6. additionThe product containing fractions
  7. concentrationconcentrated in vacuo
  8. washwas washed with MeOH
  9. washthe product eluted with 0.5M NH3/MeOH
  10. concentrationThe basic fractions were concentrated under reduced pressure

Sources & evidence

ORD record
ord-0eea2f9a62a34fc98a1f31993a5b5321
Source dataset
uspto-grants-2015_07
Patent number
US09090628B2

Reaction notes

Loading…